MCE products for research use only. We do not sell to patients.

Imiquimod

MCE China：Imiquimod

Brand：MedChemExpress (MCE)

Cat. No.HY-B0180

CAS：99011-02-6

Synonyms：R 837

Purity：99.96%

Storage：Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year

Shipping：Room temperature in continental US; may vary elsewhere.

Description：Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19.

In Vivo：Imiquimod (IMQ) can be used to induce psoriasis models[5]. .f12{ font-size: 12px; } .fwb{ font-weight: bold; } .lh22{ line-height: 22px;; } .lh23 { line-height: 23px; } .pl13{ padding-left: 13px;; } .part { margin-top: 18px; } .mold-first-tit { width: 100%; height: 44px; line-height: 44px; background: #F9F7FB; border-bottom: 1px solid #EBE4F6; padding-left: 16px; box-sizing: border-box; margin-bottom: 17px; } .mold-second-tit:before { content:""; width: 6px; height: 6px; display: inline-block; border-radius: 50%; background: rgba(255,102,0,0.4); margin-right: 12px; position: relative; top: -3px; } .lft-border { border-left: 1px dotted #EBE4F6; padding-right: 12px; margin-left: 3px; box-sizing: border-box; padding-bottom: 12px; } /* .part .dec:last-child { border-bottom: 0; } */ .dec { margin: 10px 15px 0; padding-bottom: 10px; border-bottom: 1px dashed #EBE4F6; } .btm-border { border-left: 1px dashed #EBE4F6; } .text-bg { margin-top: 10px; background: #FFFBF1; padding: 14px; border-bottom: 0; position: relative; } .text-note-bg { margin-top: 10px; background: #FFFDF7; padding: 12px; border-bottom: 0; position: relative; } .text-note { width: 51px; height: 20px; line-height: 20px; background: #FFE2AA; text-align: center; border-radius: 0 0 8px 0; position: absolute; top: 0; left: 0; } .text-note-dec { margin-top: 15px;; } Induction of psoriasis Model[5] Background Lmiquimod (IMQ) induces inflamed scaly skin lesions resembling plaque-type psoriasis. IMQ induces epidermal expression of IL-23, IL-17A, and IL-17F, as well as an increase in splenic Th17 cells. Specific Mmodeling Methods Mice: BALB/c • male • 8-week-old Administration: 3.125 mg/day • skin • 6 days Note IMQ cream preparation [7]:(1) Prepare BM of lipidsSTA and OA were melted at 75 °C followed by the addition of IMQ (3.5% of the BM, w/w) under continuous stirring.Polysorbate 80 and stearoyl polyoxyl-32 glycerides at a 50:50 ratio were dispersed in water heated separately to 75 °C and added to the BM phase under continuous stirring.(2) Prepare nanostructured lipid carriers (NLCs)The mixture was then subjected to high-shear homogenization followed by ultrasonication. The mixture was then rapidly cooled in an ice bath to allow the formation of NLCs. Modeling Indicators Behavior Observation: Inducedthe back skin of the mice started to display signs of erythema, scaling, andthickening. Resulted in hyperproliferative keratinocytes and adisturbed epidermal differentiation (parakeratosis). Correlated Product(s): / Opposite Product(s): /

IC50 & Target：TLR7 HSV-1

Hot selling product：Ezetimibe  | L-Leucine  | PF-9366  | NSC 74859  | Psoralidin  | Midostaurin  | S100A4, Mouse (His)  | Tetrakis(triphenylphosphine)palladium  | Atorvastatin  | UNC2004

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

References：

[1]. Athina Angelopoulou, et al. Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19. Environ Res. 2020 Sep; 188: 109858.  [Content Brief]

[2]. Aditya K Gupta, et al. Imiquimod: a review. J Cutan Med Surg. Nov-Dec 2002;6(6):554-60.  [Content Brief]

[3]. Yuji Kan, et al. Imiquimod suppresses propagation of herpes simplex virus 1 by upregulation of cystatin A via the adenosine receptor A1 pathway. J Virol. 2012 Oct;86(19):10338-46.  [Content Brief]

[4]. Michael P Schön, et al. The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion. J Invest Dermatol. 2006 Jun;126(6):1338-47.  [Content Brief]

[5]. Leslie van der Fits, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol. 2009, 182, 9.  [Content Brief]

[6]. Ajla Smajlović, et al. Molecular and histopathological profiling of imiquimod induced dermatosis in Swiss Wistar rats: contribution to the rat model for novel anti-psoriasis treatments. Mol Biol Rep. 2021, 48, 5.  [Content Brief]

[7]. Sangseo Kim, et al. Development and Optimization of Imiquimod-Loaded Nanostructured Lipid Carriers Using a Hybrid Design of Experiments Approach. Int J Nanomedicine. 2023.  [Content Brief]